Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

• Published in: Annals of hematology Vol. 100; no. 7; pp. 1871 - 1878
• Main Authors: Angenendt, Linus, Hilgefort, Isabel, Mikesch, Jan-Henrik, Schlüter, Bernhard, Berdel, Wolfgang E., Lenz, Georg, Stelljes, Matthias, Schliemann, Christoph
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.07.2021; Springer Nature B.V
• Subjects: Hematology; Leukemia; Medicine; Medicine & Public Health; Oncology; Original; Original Article; Stem cell transplantation; Stem cells; GVHD; Allogeneic hematopoietic stem cell transplantation; Magnesium; GVL; Acute myeloid leukemia
• ISSN: 0939-5555; 1432-0584
• DOI: 10.1007/s00277-020-04382-y

Low intake of magnesium has been associated with the occurrence of lymphomas and decreased magnesium levels suppress the cytotoxic function of T cells and natural killer cells in patients with “X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection, and neoplasia” (XMEN) syndrome. These cell types are also important mediators of immune-mediated effects after allogeneic hematopoietic stem cell transplantation. Here, we show that high posttransplant magnesium levels independently associate with a lower incidence of relapse, a higher risk of acute graft-versus-host disease, and a higher non-relapse mortality in 368 patients with acute myeloid leukemia from our center. Magnesium serum levels might impact on donor-cell-mediated immune responses in acute myeloid leukemia.